Screening

Intellicyt iQue3 –Faster, Smarter Flow Cytometry

8 July 2019 | By IntelliCyt Corporation

This advanced flow cytometry platform is a complete instrument, reagents and software solutions streamlined to rapidly generate results not just data.

Titian Software Ltd

Video: Ethical and regulatory use of biospecimens in the EU

1 July 2019 | By BioIVT

Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.

Video: Multiplex IHC and digital analysis for immuno-oncology

1 July 2019 | By BioIVT

High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.

Compound and fragment screening by native mass spectrometry

14 June 2019 | By Nicola Burgess-Brown, Rod Chalk

Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.

Screening and beyond in drug discovery

14 June 2019 | By Sheraz Gul (Head of Drug Discovery at the Fraunhofer Institute for Molecular Biology and Applied Ecology)

Progressing drug discovery projects to a stage that attracts commercial interest is a challenging endeavour, evidenced by the fact that only a small proportion of drug discovery projects are successfully progressed to such a stage. A major cause of this is the lack of comprehensive profiling of compounds prior to…

First blood-brain barrier chip using stem cells developed

13 June 2019 | By Drug Target Review

Researchers have, for the first time, duplicated a patient's blood-brain barrier (BBB), creating a human BBB chip with stem cells.

First in vitro lung cancer test launched

12 June 2019 | By Victoria Rees (Drug Target Review)

A new in vitro lung cancer diagnostic test has been launched by Roche Diagnostics to provide improved detection of cancer.

CRISPR/Cas9-engineered cancer models: the next step forward for targeted cancer therapy

11 June 2019 | By Elizabeth Turner Gillies PhD, Fang Tian PhD

The advent of CRISPR/Cas9 gene editing, together with the plummeting cost of whole-genome sequencing, has cleared a path for the development of customised cancer cell models. Here, we discuss recent developments in the field and challenges associated with targeted-therapy resistance.

Application note: Detection of anti-drug antibody (ADA) using single molecule counting (SMC^TM) technology

11 June 2019 | By Merck

All biological therapeutics have the potential to induce an immunemediated response ranging from benign to severe adverse effects.

Researchers identify chemotherapy-enhancing molecule

10 June 2019 | By Victoria Rees (Drug Target Review)

A new study has found a small molecule which prevents cancer cells from mutating and becoming resistant to chemotherapy.

Screening In-Depth Focus 2019

7 June 2019 | By Drug Target Review

This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.

Phenotypic profiling in drug discovery

5 June 2019 | By Ina Rothenaigner, Kamyar Hadian, Sean Lin

Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…

Drug Target Review Issue 2 2019

5 June 2019 | By Drug Target Review

In this issue: novel approaches to produce radiolabelled antibodies, the use of CRISPR/Cas9 to accelerate the development of targeted therapies and utilisation of stem cells to study the effects of cannabis on neuronal development.

Autoimmune disorders could be treated with new compounds

30 May 2019 | By Drug Target Review

New research could lead to novel treatments for autoimmune disorders and sheds light on the causes of autoimmunity.